Patents by Inventor Kelly Carles-Kinch

Kelly Carles-Kinch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120121582
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of non-neoplastic hyperproliferative epithelial and/or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and/or aberrant angiogenesis. Non-limiting examples of such disorders include cirrhosis, fibrosis (e.g.
    Type: Application
    Filed: January 26, 2011
    Publication date: May 17, 2012
    Applicant: Medimmune, LLC
    Inventors: Michael S. Kinch, Kelly Carles-Kinch
  • Publication number: 20100298545
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: November 25, 2009
    Publication date: November 25, 2010
    Inventors: Michael S. Kinch, Kelly Carles-Kinch, Jane c. Stewart
  • Publication number: 20100278838
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low Koff, thereby, inhibiting tumor cell growth and/or metastasis.
    Type: Application
    Filed: April 7, 2010
    Publication date: November 4, 2010
    Applicant: MEDIMMUNE, LLC
    Inventors: Michael S. Kinch, Kelly Carles-Kinch, Peter Kiener, Solomon Langermann
  • Publication number: 20100260749
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of non-neoplastic hyperproliferative epithelial and/or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and/or aberrant angiogenesis. Non-limiting examples of such disorders include cirrhosis, fibrosis (e.g.
    Type: Application
    Filed: August 4, 2008
    Publication date: October 14, 2010
    Applicant: MEDIMMUNE, INC.
    Inventors: Michael S. Kinch, Kelly Carles-Kinch
  • Publication number: 20100166657
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 and agonize EphA4. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 and inhibit cancer cell colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that preferentially binds to an EphA4 epitope that is exposed on cancer cells but not non-cancer cells.
    Type: Application
    Filed: September 11, 2009
    Publication date: July 1, 2010
    Applicant: MEDIMMUNE, LLC
    Inventors: Michael S. Kinch, Kelly Carles-Kinch
  • Publication number: 20100143345
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: June 5, 2009
    Publication date: June 10, 2010
    Applicants: MEDIMMUNE, LLC, PURDUE RESEARCH FOUNDATION
    Inventors: Michael S. Kinch, Kelly Carles-Kinch, Jane C. Stewart
  • Patent number: 7604799
    Abstract: The invention provides agonistic anti-EphA4 antibodies.
    Type: Grant
    Filed: June 7, 2004
    Date of Patent: October 20, 2009
    Assignee: Medimmune, LLC
    Inventors: Michael S. Kinch, Kelly Carles-Kinch
  • Patent number: 7402298
    Abstract: The invention provides a monoclonal antibody, a fragment thereof, or a molecular complex thereof that binds to an extracellular domain of an EphA2 receptor molecule, wherein binding of the monoclonal antibody or fragment thereof to the EphA2 receptor molecule present in the membrane of a cancer cell favorably alters activity of the EphA2 receptor molecule. The invention further relates to methods of making and using the monoclonal antibodies, fragments, and molecular complexes regarding the same. The monoclonal antibodies of the present invention target the extracellular domain of EphA2 and operate to redirect the function of EphA2 to selectively block the growth and invasiveness of metastatic cells. The invention thus makes possible therapeutic strategies that optimally target metastatic cells while preventing collateral damage to normal tissues.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: July 22, 2008
    Assignees: Purdue Research Foundation, SmithKline Beecham Corporation
    Inventors: Michael Scott Kinch, Kelly Carles-Kinch, Katherine E Kilpatrick
  • Publication number: 20070166314
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low Koff, thereby, inhibiting tumor cell growth and/or metastasis.
    Type: Application
    Filed: March 12, 2007
    Publication date: July 19, 2007
    Inventors: Michael Kinch, Kelly Carles-Kinch, Peter Kiener, Solomon Langermann
  • Publication number: 20070134254
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: January 5, 2007
    Publication date: June 14, 2007
    Inventors: Michael Kinch, Kelly Carles-Kinch, Jane Stewart
  • Publication number: 20070086943
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: October 6, 2006
    Publication date: April 19, 2007
    Inventors: Michael Kinch, Kelly Carles-Kinch, Jane Stewart
  • Patent number: 7101976
    Abstract: The invention provides a monoclonal antibody, a fragment thereof, or a molecular complex thereof that binds to an extracellular domain of an EphA2 receptor molecule, wherein binding of the monoclonal antibody or fragment thereof to the EphA2 receptor molecule present in the membrane of a cancer cell favorably alters activity of the EphA2 receptor molecule. The invention further relates to methods of making and using the monoclonal antibodies, fragments, and molecular complexes regarding the same. The monoclonal antibodies of the present invention target the extracellular domain of EphA2 and operate to redirect the function of EphA2 to selectively block the growth and invasiveness of metastatic cells. The invention thus makes possible therapeutic strategies that optimally target metastatic cells while preventing collateral damage to normal tissues.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: September 5, 2006
    Assignees: Purdue Research Foundation, SmithKline Beecham Corporation
    Inventors: Katherine E Kilpatrick, Michael Scott Kinch, Kelly Carles-Kinch
  • Publication number: 20060122138
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of non-neoplastic hyperproliferative epithelial and/or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and/or aberrant angiogenesis. Non-limiting examples of such disorders include cirrhosis, fibrosis (e.g.
    Type: Application
    Filed: October 27, 2005
    Publication date: June 8, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: Michael Kinch, Kelly Carles-Kinch
  • Publication number: 20060121043
    Abstract: The present invention provides methods and compositions designed for the treatment, management, and/or amelioration of an infection, in particular an intracellular pathogen infection, such as a viral, bacterial, protozoa or fungal infection. In particular, the present invention provides methods for treating, managing, preventing and/or ameliorating an infection where the expression of EphA2 is upregulated in infected cells (e.g., infected epithelial cells), said methods comprising administering to a subject an effective amount of one or more EphA2/EphrinA1 Modulators. In accordance with the present invention, such methods may also comprise the administration of one or more therapies other than an EphA2/EphrinA1 Modulator.
    Type: Application
    Filed: October 27, 2005
    Publication date: June 8, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: Michael Kinch, Kelly Carles-Kinch
  • Publication number: 20060121042
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of various disorders associated with aberrant expression and/or activity of one or more Eph receptor tyrosine kinase family members and/or one or more Eph receptor ligands, particularly the Ephrins. In particular, the invention provides methods for the treatment, management, prevention and/or amelioration of a disorder associated with aberrant expression and/or activity(ies) of one or more Eph receptors and/or one or more Ephrins, the method comprising administering to a subject in need thereof an effective amount of one or more Eph/Ephrin Modulators. The present invention further relates to methods of modulating antibody specificity by tailoring the affinity to cognate antigens.
    Type: Application
    Filed: October 27, 2005
    Publication date: June 8, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: William Dall'Acqua, Melissa Damschroder, Michael Kinch, Kelly Carles-Kinch
  • Publication number: 20050152899
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: November 19, 2004
    Publication date: July 14, 2005
    Inventors: Michael Kinch, Kelly Carles-Kinch, Jane Stewart
  • Publication number: 20050013819
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 and agonize EphA4. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 and inhibit cancer cell colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that preferentially binds to an EphA4 epitope that is exposed on cancer cells but not non-cancer cells.
    Type: Application
    Filed: June 7, 2004
    Publication date: January 20, 2005
    Inventors: Michael Kinch, Kelly Carles-Kinch
  • Publication number: 20040091486
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: May 12, 2003
    Publication date: May 13, 2004
    Inventors: Michael S. Kinch, Kelly Carles-Kinch, Jane C. Stewart
  • Publication number: 20040028685
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low Koff, thereby, inhibiting tumor cell growth and/or metastasis.
    Type: Application
    Filed: May 12, 2003
    Publication date: February 12, 2004
    Inventors: Michael S. Kinch, Kelly Carles-Kinch, Peter Kiener, Solomon Langermann